- Home
- IOVA vs SCSC Comparison
IOVA vs SCSC Comparison
Compare IOVA & SCSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- SCSC
- Stock Information
- Founded
- IOVA 2007
- SCSC 1992
- Country
- IOVA United States
- SCSC United States
- Employees
- IOVA N/A
- SCSC N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- SCSC Retail: Computer Software & Peripheral Equipment
- Sector
- IOVA Health Care
- SCSC Technology
- Exchange
- IOVA Nasdaq
- SCSC Nasdaq
- Market Cap
- IOVA 975.1M
- SCSC 892.3M
- IPO Year
- IOVA N/A
- SCSC 1994
- Fundamental
- Price
- IOVA $2.69
- SCSC $44.63
- Analyst Decision
- IOVA Buy
- SCSC
- Analyst Count
- IOVA 11
- SCSC 0
- Target Price
- IOVA $11.90
- SCSC N/A
- AVG Volume (30 Days)
- IOVA 16.7M
- SCSC 300.9K
- Earning Date
- IOVA 08-07-2025
- SCSC 08-21-2025
- Dividend Yield
- IOVA N/A
- SCSC N/A
- EPS Growth
- IOVA N/A
- SCSC N/A
- EPS
- IOVA N/A
- SCSC 3.00
- Revenue
- IOVA $241,525,000.00
- SCSC $3,040,810,000.00
- Revenue This Year
- IOVA $86.62
- SCSC $5.79
- Revenue Next Year
- IOVA $69.13
- SCSC $4.60
- P/E Ratio
- IOVA N/A
- SCSC $14.82
- Revenue Growth
- IOVA 636.99
- SCSC N/A
- 52 Week Low
- IOVA $1.64
- SCSC $28.75
- 52 Week High
- IOVA $12.51
- SCSC $53.90
- Technical
- Relative Strength Index (RSI)
- IOVA 54.92
- SCSC 59.75
- Support Level
- IOVA $2.44
- SCSC $39.60
- Resistance Level
- IOVA $2.85
- SCSC $45.63
- Average True Range (ATR)
- IOVA 0.24
- SCSC 1.85
- MACD
- IOVA -0.00
- SCSC 0.17
- Stochastic Oscillator
- IOVA 83.16
- SCSC 86.60
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About SCSC ScanSource Inc.
ScanSource Inc provides value-added services for technology manufacturers and sells to resellers in specialty technology markets. The firm's operations are organized in two segments: Specialty Technology Solutions and Modern Communications and Cloud. It generates maximum revenue from the Specialty Technology Solutions segment. The Specialty Technology Solutions segment includes the company's business in mobility and barcode, POS, payments, security and networking technologies. Geographically, it derives a majority of revenue from the United States.